Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer
Abstract Background Epithelial ovarian cancer (EOC) is a highly lethal malignancy. Improvement in genetic characterization of EOC patients is required to propose new potential targets, since surgical resection coupled to chemotherapy, presents several limits such as cancer recurrence and drug resist...
Main Authors: | Luyao Guan, Zhang Li, Feifei Xie, Yuzhi Pang, Chenyun Zhang, Haosha Tang, Hao Zhang, Chun Chen, Yaying Zhan, Ting Zhao, Hongyuan Jiang, Xiaona Jia, Yuexiang Wang, Yuan Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-020-01557-3 |
Similar Items
-
RET Inhibitors in Non-Small-Cell Lung Cancer
by: Priscilla Cascetta, et al.
Published: (2021-09-01) -
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
by: Begümhan Demir Gündoğan, et al.
Published: (2021-09-01) -
Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
by: Qin Huang, et al.
Published: (2020-05-01) -
Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
by: Fallahi P, et al.
Published: (2019-08-01) -
Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01)